



JPW

PATENT
Attorney Docket 053529-5007-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<i>In re</i> Application of: Berkley Lynch <i>et al.</i>)	
)	
Application No. 10/725,189)	Group Art Unit: 1649
)	
Filed: December 2, 2003)	Examiner: Chang Yu Wang
)	
Title: Methods for the Identification of Agents for)	
the Treatment of Seizures, Neurological)	
Diseases, Endocrinopathies and Hormonal)	
Diseases)	

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Window, **Mail Stop Amendment**
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(e) (1)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(e) (1), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449 form. To the best of the undersigned's knowledge, each item of information contained in the Information Disclosure Statement was first cited in an International Search Report from the International Searching Authority (ISA/US) in a related PCT application (PCT/US03/038112) no more than three months prior to the filing of this Information Disclosure Statement. Accordingly, Applicants do not believe a fee is due for filing this Information Disclosure Statement.

A copy of the International Search Report, dated March 8, 2006, for related PCT application PCT/US03/038112 is attached hereto. Each of the documents cited in the International Search Report is listed on the attached Form PTO-1449 or on a previously submitted Form PTO-1449.

With the exception of a published U.S. Patent application, copies of the listed documents are attached. Applicants respectfully request that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If it should be determined that the listed documents constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there are any additional fees due in connection with the filing of this response, please charge the fees to our Deposit Account No. 50-0310. If a fee is required for an extension of time under 37 C.F.R. §1.136 not accounted for above, such an extension is requested and the fee should also be charged to our Deposit Account.

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP

Dated: May 4, 2006

Morgan, Lewis & Bockius LLP


Customer No. 09629

1111 Pennsylvania Avenue

Washington, D.C. 20004

Phone: (202)-739-3000

By:


Sally P. Teng
Registration No. 45,397

(Use several sheets if necessary)

1449 MAY 04 2006 PATENT & TRADEMARK OFFICE U.S.

Group Art Unit: 1764

Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date
	US 2002/0082252	06/27/2002	Hochman	514	214	1/23/2002

[illegible]

Sigma (2003) Product Information for n-Docecul beta-D-maltoside, Product Number D4641

Date Considered

1-WA/2562747.1